We performed below the IBD audit for:

- Sigmoidoscopy in 72 hours (28% vs 99%)
- Prescribing Ca/vit D (65% vs 74%)
- Median time to surgery (9 vs 7.5 days)

Important standards of IBD nurse and dietician review maintained. Delay in endoscopic evaluation and therefore time to surgery indicate there has been a slipping of standards in ASC care. This may be related to less direct ward continuity.

Our data show a drop in performance (access to endoscopy and time to surgery). They have allowed us to critically appraise our acute IBD service thus leading to care delivery change and an education package for medical and surgical directorates. A repeat audit is planned in 24 months to demonstrate quality improvement as a result of this.

PWE-044 THE IBD BIORESOURCE: PROGRESSING FROM GENETICS TO FUNCTION AND CLINICAL TRANSLATION IN CD & UC

^{1,2}Laetitia Pele*, ^{1,2}Rachel Simpkins, ^{1,2}Catherine Thorbinson, ^{1,2}Deepthy Francis, ^{1,2}Sophie Lewis, ²Rasha Shawky, ^{1,2}Miles Parkes, ^{1,2}UK IBD Genetic Consortium. ¹Department of Medicine, University of Cambridge, UK, Cambridge, UK; ²IBD Bioresource, NIHR BioResource, Cambridge, UK, Cambridge, UK

10.1136/gutjnl-2018-BSGAbstracts.176

Introduction The Inflammatory Bowel Disease (IBD) BioResource was established by the UK IBD Genetics Consortium and the NIHR BioResource in 2016 to expedite the clinical translation of recent genetics advances and support important IBD research. It recruits patients from hospitals UK-wide, the aim being to enlist 25 000 participants who can be further invited for future research studies based on genotype and/or phenotype. DNA samples will also be used in on-going IBD genetics analyses by the UK IBD Genetics Consortium.

Methods The Main cohort comprises individuals with established Crohn's Disease (CD) and Ulcerative Colitis (UC). Both clinical and self-reported phenotype data are collected, alongside plasma, serum and DNA samples for whole Genome Sequencing. The Inception cohort aims to recruit a sub-set of 1000 individuals newly diagnosed with IBD that will provide more detailed sampling, unconfounded by drug treatment or effects of surgery and includes stool, biopsy tissue and whole blood for RNA. This cohort offers a unique resource to undertake transcriptomic, meta-genomic, metabolomic and proteomic studies and facilitate research into determinants, predictors and biomarkers of IBD disease course and treatment response. In addition to Stage 1 recruitment, the IBD BioResource panel can be accessed by any researchers (both academic and commercial) with ethically approved proposals and may involve a range of possible options, such as access to data or samples or recall of genotype-selected participants to donate further samples or trial novel therapies.

Results 24 months in, we have 59 hospitals active and ~30 in set-up.

Main Cohort: over 8000 patients have been recruited – CD/UC 4,390/3,832.

CD phenotypes: extent – 31% ileal, 32% ileo-colonic, 31% colonic, 28% with peri-anal involvement; behaviour – 68% inflammatory, 21% stenosing and 11% penetrating.

5048 (61%) have been prescribed thiopurines and 2324 (28%) required treatment cessation. 3842 (47%) have received anti-TNF α therapy.

45% CD and 5% UC have required surgery. Most subjects are recruited in medical gastroenterology clinics so there are biases in this dataset. We will provide updates and breakdown of numbers at the meeting and discuss downstream stage 2 studies.

Inception Cohort: has been launched and is being rolled out nationally.

Conclusion The IBD BioResource and its network are on course to generate an accessible platform of patients and their data that will facilitate high quality translational IBD research.

PWE-045 VEDOLIZUMAB RESULTS IN REDUCED HOSPITALISATION AND STEROID USE OVER 1-YEAR: RESULTS FROM THE SCOTTISH VEDOLIZUMAB COHORT

¹Nikolas Plevris*, ¹Cher Chuah, ¹Phil Jenkinson, ²R Allen, ²P Baker, ³Paul Brennan, ¹Antonia Churchhouse, ¹S Din, ⁴Emma Donoghue, ²Daniel Gaya, ³Max Groome, ⁵H Jafferbhoy, ¹G Jones, ²Jonathan Macdonald, ²Morag MacMaster, ³Craig Mowat, ²G Naismith, ¹C Noble, ⁶L Potts, ²E Saffouri, ²JP Seenan, ⁵A Sengupta, ¹Alan Shand, ³P Shasi, ³J Todd, ²J Veryan, ⁶A Watson, ¹E Watson, ⁴D Watts, ¹I Amott, ¹C Lees. ¹The Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK; ²NHS Greater Glasgow and Clyde, Glasgow, UK; ³NHS Tayside, Dundee, UK; ⁴NHS Forth Valley, Forth Valley, UK; ⁵NHS Fife, Kirkcaldy, UK; ⁶NHS Highlands, Inverness, UK

10.1136/gutjnl-2018-BSGAbstracts.177

Introduction The GEMINI trials and an increasing body of real-world data have demonstrated the effectiveness and safety of vedolizumab (VDZ) in IBD. However, there is limited available data about its effect on hospitalisations and steroid use. Our aim was to address this in a large real-world cohort of IBD patients from across Scotland.

Methods A multicenter retrospective cohort analysis of medical records was performed across 7 Scottish healthcare trusts. Primary outcomes were hospitalisation rates and overall steroid use in patients remaining on VDZ. Secondary outcomes were safety and intention to treat steroid free remission rates in patients with active disease. All data were prospectively collected as part of routine clinical care. Baseline demographics, clinical scores (HBI or Partial Mayo), faecal calprotectin (FC), endoscopy and radiology at 3, 6 and 12 months was recorded where available. Active disease was defined as endoscopic or radiographic evidence of disease or FC >200 mcg/g. Clinical remission was defined as HBI <5 or Partial Mayo <2. Biochemical remission was defined as FC <200 mcg/g.

Results 340 (137 UC and 203 CD) patients were included in the primary analysis with a median follow-up of 9.4 months. Hospitalisation rates per patient-year were 0.60, 0.67, 0.36 and 0.16 at baseline, 3, 6 and 12 months of treatment respectively. Total number of hospitalisations reduced by 52.5% from 204 (12 months prior to VDZ) to 97 (12 months after VDZ). Proportion of patients on concomitant steroids reduced from 39.7% to 16.7% (n=332), 8.1% (n=270), 9.3% (n=194) at 3, 6 and 12 months respectively. In patients with active CD (n=153, 75.4%) steroid free clinical and steroid free biochemical remission rates were; 54.4% and 30.2% at 3 months; 47.7% and 32.1% at 6 months; 28.6% and 33.9% at 12 months. In patients with active UC (n=112, 81.8%) steroid free clinical and steroid free biochemical remission rates were; 57.4% and 40.9% at 3 months; 51.6% and 39.1% at 6 months; 37.5% and 41.2% at 12 months. Our cohort received >2066 VDZ infusions, 2 (0.6%) patients developed infusion reactions, 9 (2.6%) patients developed serious infections and 17 (5.0%) serious adverse events.

Conclusions VDZ is associated with reduced hospitalisation and steroid use over 1 year. Steroid free remission rates and safety profile is in keeping with the published literature.

PWE-046 TH17 CELLS DOMINATE THE COLONIC MUCOSAL IMMUNE RESPONSE IN PRIMARY SCLEROSING CHOLANGITIS ASSOCIATED COLITIS

^{1,2,3}Mohammed Quraishi*, ⁴Animesh Acharjee, ²Evaggelia Liaskou, ⁵Amanda Rossiter, ^{2,3,4}Subrata Ghosh, ¹Chris Tselepis, ⁴Georgios Gkoutos, ²David Withers, ^{2,3,4}Gideon Hirschfield, ^{1,2,3,4}Tariq Iqbal. ¹Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK; ²Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; ³University Hospital Birmingham, Birmingham, UK; ⁴Institute of Translational Medicine, Birmingham, UK; ⁵Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK

10.1136/gutjnl-2018-BSGAbstracts.178

Introduction Primary sclerosing cholangitis (PSC) is an idiopathic chronic cholestatic liver disease associated with ulcerative colitis (UC). PSC is thought to be a consequence of a genetically predisposition, dysregulated immune response and unknown factors including the gut microbiome. The colonic mucosal immune response in PSC associated colitis (PSC-UC), however, has been poorly defined. In this study, we analysed the characteristics of colonic mucosal CD4 T cells in patients with PSC-UC.

Methods Colon biopsies were collected from patients with PSC-UC (n=13), UC (n=10) and controls (n=20). One patient with PSC-UC and one patient with UC was on biologics. Three patients with PSC and three with UC had colonic inflammation. Lamina propria mononuclear cells were analysed by flow cytometry.

Results PSC-UC and UC were characterised by a significantly higher frequency of colonic mucosal CCR6 +CD161+Th17 cells compared to controls (17.5% vs 11.1%; p=0.009% and 21.02% vs 11.1%; p=0.01 respectively). CCR6-CXCR3 +CCR5+Th1 cells were significantly lower in PSC-UC compared to controls (15.46% vs 24.50% respectively; p 0.01). CD127-CD25+FoxP3+T regulatory cell frequencies was elevated and CCR6-CCR5-CXCR3- Th2 frequencies were reduced only in UC compared to controls (7.6% vs 4.38%; p=0.007% and 14.84% vs 8.77%; p=0.02 respectively). Significantly increased frequencies of IL17 producing CD4 cells were observed in both PSC-UC and UC compared to controls (7.75% vs 4.7%; p<0.001% and 7.251% vs 4.70%; p=0.006 respectively). Although there were no differences in TNF α and IFN γ producing CD4 cells, patients with PSC-UC had a

significantly higher frequency of IL17/IFN γ dual producing CD4 cells compared to controls (2.79% vs 1.76% respectively; p=0.03). Correlation analysis of PSC-UC and controls demonstrated that Th17 frequencies positively correlated with increasing frequencies of IL17 producing cells and negatively with Th1 (p<0.05).

Conclusions Our study demonstrates for the first time that the colonic mucosal immune response in PSC-UC is characterised by significantly higher Th17 cells and lower Th1 cells compared to controls. Patients with PSC-UC have higher IL-17 and IL17/IFN γ dual producing CD4 cells. Our findings highlight the need to explore the role of key players such as the gut microbiome in mucosal T cell homeostasis and Th1/Th17 plasticity in PSC.

PWE-047 THERAPEUTIC DRUG MONITORING FOR INFLIXIMAB & ADALIMUMAB IN IBD: PRACTICE PATTERNS, UNDERSTANDING & INTERPRETATION

¹Mark Samaan, ²Zehra Arkir, ¹Peter Irving, ³Charlotte Chuter*. ¹IBD Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK; ²Vaiphath, St Thomas' Hospital, London, UK; ³York Teaching Hospital, UK

10.1136/gutjnl-2018-BSGAbstracts.179

Introduction The use of therapeutic drug monitoring (TDM) for infliximab and adalimumab in the treatment of inflammatory bowel disease (IBD) is becoming increasingly commonplace. In cases of non-response (primary or secondary) TDM can provide a clearer understanding of the cause of treatment failure and offer a rationale for steps taken to recapture response. However, several factors regarding its use remain uncertain such as minimum therapeutic thresholds, the relevance of antidrug antibodies found in the presence of detectable drug, and the benefits of TDM during remission.

Methods We designed a survey that included 5 TDM-based clinical scenarios, for which the 'most appropriate' responses were based on the Building Research in IBD Globally (BRIDGE) groups 'Anti-TNF Optimizer' (<http://www.bridgeibd.com/anti-tnf-optimizer>). This resource combines available TDM evidence with expert consensus. A link to our online survey tool was sent to various IBD clinician groups in June 2017 including members of the British Society of Gastroenterology, Royal College of Nursing IBD Network and the gastroenterology special interest group of the UK Clinical Pharmacy Association.

Results We received 142 responses. Of these, 110 (77%) were complete, comprising 50 (45%) consultants, 30 (27%) trainees,

Abstract PWE-047 Figure 1 Lower therapeutic thresholds selected by respondents for IFX and ADA